• Thursday, January 11, 2024 @ 12:00 am

Cellestia is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD)

The project aims at developing CB-103 as first-in-class drug to prevent GvHD in allogeneic-Hematopoetic Stem Cell Transplant (HSCT) patients. With this novel approach, Cellestia envisions a transformative shift in the management of GvHD from treatment to prevention.

“We extend our sincere thanks to Innosuisse for recognizing the potential of CB-103 in enhancing the lives of patients grappling with GvHD” said Raj Lehal, CEO of Cellestia.

About GVHD
GvHD stands as the leading non-relapse-related cause of mortality in individuals undergoing allo-HSCT, impacting over 50% of the patients. The standard of care for prevention of GvHD is insufficient to prevent its occurrence, contributing to the persistent high mortality rates in this patient population.

You may also be interested in